Market Analysis and Insights:- Global Sjögren’s Syndrome Market
Global Sjögren’s Syndrome Market By Type (Primary Sjögren’s Syndrome, Secondary Sjögren’s Syndrome), Symptoms (Dry Eyes, Dry Mouth, Others), Diagnosis (Blood Tests, Eye Tests, Lip Biopsy, Others), Treatment (Medication, Surgery, Others), Drugs (Salagen, Evoxac, Plaquenil, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2027
Market Analysis: Global Sjögren’s Syndrome Market
Global Sjögren’s syndrome market is rising gradually with a steady CAGR of 4% in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. Increasing incidence of Sjogren's syndrome and presence of a strong pipeline for the disease is contributing towards this market growth in the upcoming years.
Market Definition: Global Sjögren’s Syndrome Market
Sjögren's syndrome is an autoimmune disease that causes dryness of the mouth and eyes. This syndrome is associated with other immune system disorders such as rheumatoid arthritis and lupus. The major symptoms of this syndrome are dryness in eyes and mouth followed by joint pain, swollen salivary glands and others. There are two types of Sjogren's syndromes i.e. primary Sjogren's syndrome and secondary Sjogren's syndrome.
The prevalence rate of Sjogren's syndrome is estimated to be 0.1 to 4% of global population. The occurrence of this disease in women is 10 times higher than men. Sjogren's syndrome can occur in any age group, but it is most common in age of 45 to 55 years.
Get More Insight About the Global Sjögren’s Syndrome Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sjgrens-syndrome-market
Market Drivers
- Increasing incidence of Sjogren's syndrome and other autoimmune diseases are major drivers for the growth of market
- Rise in geriatric population susceptible to autoimmune diseases will drive the market growth
- Improvement in health care expenditure in many countries for the disease treatmnet will also boost the market growth in the forecast period
- Strong drug pipeline present for the disease is another factor driving the market growth
Market Restraints
- Unwanted immunogenicity caused by drugs used for treatment of Sjogren's syndrome hampers the market growth
- Lack of awareness about sjogren's syndrome acts as restrain to the market growth
- Lack of proper treatment of Sjogren's syndrome is another factor which hinders the market growth
Segmentation: Global Sjögren’s Syndrome Market
By Type
- Primary Sjögren’s Syndrome
- Secondary Sjögren’s Syndrome
By Symptoms
- Dry Eyes
- Dry Mouth
- Others
By Diagnosis
- Blood Tests
- Eye Tests
- Lip Biopsy
- Others
By Treatment
- Medication
- Surgery
- Others
By Drugs
- Salagen
- Evoxac
- Plaquenil
- Others
By End Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Distribution Channels
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Others
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- Italy
- U.K.
- France
- Spain
- Netherlands
- Belgium
- Switzerland
- Turkey
- Russia
- Hungary
- Lithuania
- Austria
- Ireland
- Norway
- Poland
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Vietnam
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Peru
- Rest of South America
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Israel
- Egypt
- Rest of Middle East and Africa
Know More About this Report @ https://www.databridgemarketresearch.com/reports/global-sjgrens-syndrome-market
Key Developments in the Market:
- In May 2019, IntelGenx Corp. received the U. S. patent from the United States Patent and Trademark Office for design and manufacturing of topical oral films (TOF) for treatment of Sjögren’s syndrome and other conditions such as gingivitis, buccal ulcers and canker sores. This patent is entitled as “Film Dosage Form with Extended Release Mucoadhesive Particles.” This patent issue provides intellectual property rights to the company for manufacturing and marketing exclusivity of topical oral films (TOF)
- In April 2019, Advanz Pharmaceutical acquired the global marketing rights of Salagen (pilocarpine hydrochloride) from Eisai Co., Ltd. Salagen is used for treatment of dry mouth in patients suffering from Sjögren’s syndrome. In this acquisition Advanz Pharmaceutical has received the marketing and commercialization approval of salagen worldwide except Japan
Competitive Analysis:
Global Sjögren’s syndrome marketc is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Sjögren’s syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Key Market Players:
Few of the major competitors currently working in the global Sjögren’s syndrome market are Advanz Pharmaceutical, Eisai Co., Ltd.,., Novartis AG, AstraZeneca, Genentech, Inc., Nicox, ALLERGAN, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Amgen Inc., Lupin, Kissei Pharmaceutical Co., Ltd., Pfizer Inc., Santen Pharmaceutical Co., Ltd., Bausch Health, Resolve Therapeutics, Wize Pharma Inc. among others.
Research Methodology: Global Sjögren’s Syndrome Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Reasons to Purchase this Report
- Current and future of global Sjögren’s syndrome market outlook in the developed and emerging markets
- The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
- Regions/Countries that are expected to witness the fastest growth rates during the forecast period
- The latest developments, market shares, and strategies that are employed by the major market players
Access Full Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sjgrens-syndrome-market
About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]
Sjögren’s Syndrome Market is an autoimmune disease that causes dryness of the mouth and eyes.
The major symptoms of this syndrome are dryness in eyes and mouth followed by joint pain, swollen salivary glands and others.
primary Sjogren's syndrome and secondary Sjogren's syndrome.Global Sjögren’s syndrome market is rising gradually with a steady CAGR of 4% in the forecast period of 2020-2027.
The report contains data of the base year 2019 and historic year 2018.
Increasing incidence of Sjogren's syndrome and presence of a strong pipeline for the disease is contributing towards this market growth in the upcoming years.
Get Sample Report at : https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sjgrens-syndrome-marketCompetitive Analysis: Global Sjögren’s Syndrome MarketFew of the major competitors currently working in Global Sjögren’s Syndrome Market are Novartis AG, AstraZeneca, Genentech, Inc., Nicox, ALLERGAN, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Amgen Inc., Lupin, Kissei Pharmaceutical Co., Ltd., Pfizer Inc., Santen Pharmaceutical Co., Ltd., Bausch Health, Resolve Therapeutics, Wize Pharma Inc. among others.
Market Analysis and Insights:- Global Sjögren’s Syndrome MarketGlobal Sjögren’s Syndrome Market By Type (Primary Sjögren’s Syndrome, Secondary Sjögren’s Syndrome), Symptoms (Dry Eyes, Dry Mouth, Others), Diagnosis (Blood Tests, Eye Tests, Lip Biopsy, Others), Treatment (Medication, Surgery, Others), Drugs (Salagen, Evoxac, Plaquenil, Others), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2027Market Analysis: Global Sjögren’s Syndrome MarketGlobal Sjögren’s syndrome market is rising gradually with a steady CAGR of 4% in the forecast period of 2020-2027.
The report contains data of the base year 2019 and historic year 2018.
Increasing incidence of Sjogren's syndrome and presence of a strong pipeline for the disease is contributing towards this market growth in the upcoming years.Market Definition: Global Sjögren’s Syndrome MarketSjögren's syndrome is an autoimmune disease that causes dryness of the mouth and eyes.
This syndrome is associated with other immune system disorders such as rheumatoid arthritis and lupus.
Sjogren's syndrome can occur in any age group, but it is most common in age of 45 to 55 years.Get More Insight About the Global Sjögren’s Syndrome Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sjgrens-syndrome-market Market DriversIncreasing incidence of Sjogren's syndrome and other autoimmune diseases are major drivers for the growth of marketRise in geriatric population susceptible to autoimmune diseases will drive the market growthImprovement in health care expenditure in many countries for the disease treatmnet will also boost the market growth in the forecast periodStrong drug pipeline present for the disease is another factor driving the market growthMarket RestraintsUnwanted immunogenicity caused by drugs used for treatment of Sjogren's syndrome hampers the market growthLack of awareness about sjogren's syndrome acts as restrain to the market growthLack of proper treatment of Sjogren's syndrome is another factor which hinders the market growthSegmentation: Global Sjögren’s Syndrome MarketBy TypePrimary Sjögren’s SyndromeSecondary Sjögren’s SyndromeBy SymptomsDry EyesDry MouthOthersBy DiagnosisBlood TestsEye TestsLip BiopsyOthersBy TreatmentMedicationSurgeryOthersBy DrugsSalagenEvoxacPlaquenilOthersBy End UsersHospitalsHomecareSpecialty ClinicsOthersBy Distribution ChannelsHospital PharmacyOnline PharmacyRetail PharmacyOthersBy GeographyNorth AmericaU.S.CanadaMexicoEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaHungaryLithuaniaAustriaIrelandNorwayPolandRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaSingaporeMalaysiaThailandIndonesiaPhilippinesVietnamRest of Asia-PacificSouth AmericaBrazilArgentinaPeruRest of South AmericaMiddle East and AfricaSouth AfricaSaudi ArabiaUAEKuwaitIsraelEgyptRest of Middle East and Africa Know More About this Report @ https://www.databridgemarketresearch.com/reports/global-sjgrens-syndrome-market Key Developments in the Market:In May 2019, IntelGenx Corp. received the U. S. patent from the United States Patent and Trademark Office for design and manufacturing of topical oral films (TOF) for treatment of Sjögren’s syndrome and other conditions such as gingivitis, buccal ulcers and canker sores.
This patent is entitled as “Film Dosage Form with Extended Release Mucoadhesive Particles.” This patent issue provides intellectual property rights to the company for manufacturing and marketing exclusivity of topical oral films (TOF)In April 2019, Advanz Pharmaceutical acquired the global marketing rights of Salagen (pilocarpine hydrochloride) from Eisai Co., Ltd. Salagen is used for treatment of dry mouth in patients suffering from Sjögren’s syndrome.
Sjögren’s syndrome market is rising gradually with a steady CAGR of 4% in the forecast period of 2020-2027.
The report contains data of the base year 2019 and historic year 2018.
Increasing incidence of Sjogren's syndrome and presence of a strong pipeline for the disease is contributing towards this market growth in the upcoming years.Sjögren's syndrome is an autoimmune disease that causes dryness of the mouth and eyes.
This syndrome is associated with other immune system disorders such as rheumatoid arthritis and lupus.
The major symptoms of this syndrome are dryness in eyes and mouth followed by joint pain, swollen salivary glands and others.
There are two types of Sjogren's syndromes i.e.
Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade.
It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
In addition to other elements, the study includes:A detailed assessment of the current market landscape of drug developers engaged in the development of next generation immune checkpoint modulators.
A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators.Detailed profiles of developers of next generation immune checkpoint modulators (shortlisted on the basis of the number of pipeline products).An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis of the partnerships that have been established in this domain, in the recent past.A competitiveness analysis of biological targets, featuring insightful pictorial summaries and representations.An analysis of the initiatives of big biopharma players engaged in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Target Disease Indication Breast CancerChronic Lymphocytic LeukemiaColorectal CancerHead and Neck CancerLung CancerLupus NephritisMelanomaMultiple MyelomaPrimary Sjögren's SyndromeOthers Target Immune CheckpointB7-H3CD38CD40CD47OthersMechanism of ActionInhibitoryStimulatoryTherapeutic ModalityMonoclonal AntibodySmall MoleculeType of Therapy Monotherapy Combination TherapyRoute of AdministrationIntravenousSubcutaneousOthersKey Geographical Region North AmericaEuropeAsia-Pacific and the Rest of the World Key companies covered in the reportBristol Myers SquibbGlaxoSmithKlineIncyteNovartisTrillium Therapeutics For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Other Recent OfferingsNeoantigen Targeted Therapies Market, 2019-2030Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
Global Dry Eye Syndrome Treatment Market: Overview
Dry eye syndrome (DES) is also known as keratisis sicca and kerato-conjunctivitis sicca. People suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface, which is made up of three intertwined layers, a superficial lipid layer, produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114612/Dry-Eye-Syndrome-Treatment-Market
The two most common types of DES are DES associated with Sjogren syndrome (SS) and DES unassociated with SS. DES can also be classified as aqueous deficiency dry eye and evaporative dry eye disorder. According to TearScience Inc., in 2012, around 86% of the patients in Europe and the U.S. were suffering from DES showed symptoms of Meibomian Gland Dysfunction (MGD, blockage of meibomian glands). The blockage causes less secretion of oil in the tears, which results in evaporation of tears too quickly.
The global dry eye syndrome treatment market is primarily driven by growing geriatric population coupled with high prevalence of dry eye syndrome and growth in awareness about the diagnosis and treatment of the disease. However, the stringent drug approvals, expirations of the blockbuster drugs patents, and lack of skilled ophthalmologists are restraining the growth of DES market. According to National Health and Wellness Survey in 2013, approximately 16.4 million people are suffering from DES, which accounts for 6.8% of the total population of the U.S. Prevalence of DES increases with age, 2.7% for 18 - 34 age group and 18.6% for more than 75 age group were reported to be suffering from DES. The prevalence of DES is higher in women (8.8%) as compared to men (4.5%). According to the National Eye Institute, in the U.S the annual cost of treating DES including prescription drugs is US $3.84 billion.
Global Dry Eye Syndrome Treatment Market: Segmentation
By Product Type
- Cyclosporine
- Oral Corticosteroid
- Artificial Tears
- Omega Supplements
- Punctual Bags
- Removable Bags
- Dissolvable Bags
By Disease Type:
- Evaporative Dry Eye Syndrome
- Aqueous Dry Eye Syndrome
By Product
- Liquid Drops
- Gel
- Liquid Wipes
- Eye Ointment
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114612/Dry-Eye-Syndrome-Treatment-Market
High healthcare expenditure and increasing R&D activities in the DES treatment market is expected to propel growth of DES market in North America
Growing geriatric population coupled with high prevalence of dry eye syndrome owing to lifestyle disorders are contributing factors for the growth of DES market in the North America region.
Asia Pacific region is emerging in DES treatment market due to large pool of patient population. According to the regional population based study published in All India Ophthalmological Society, in 2012, the prevalence of DES was 40.8% with mild symptoms and 31.7% with MGD.
Global dry eye syndrome treatment market is oligopolistic in nature with few players holding majority of the share. Various strategies are adopted by market players such as new product launches, acquisitions, and agreements in order to retain market position. In September, 2017, Johnson and Johnson Vision, acquired TearScience Inc., a medical device manufacturer for treating MGD. This acquisition expanded the company’s eye health portfolio. In April 2017, Allergan received marketing approval from FDA for its TrueTear Intranasal Tear Neurostimulator.
Some of the major players operating in the global dry eye syndrome treatment market are Allergan, Novartis AG., Otsuka Pharmaceutical Co. Ltd., Valent Pharmaceuticals, Johnson and Johnson Vision, Acadia Pharmaceuticals, Allostera Pharma, I-Med Pharma Inc., Santen Pharmaceuticals Co. Ltd., AFT pharmaceuticals, Novaliq GmBh, and Auven therapeutics.
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114612/Dry-Eye-Syndrome-Treatment-Market
